A MET mutation causing exon 14 skipping in RJLC2-T3 (c-METΔE14), and ARAFS214C, identified in RJLC3-T2, have been recently reported to be oncogenic in preclinical models and lung adenocarcinoma patients34–36. Here, MET is linked to lung adenocarcinoma.